← Drug-vs-drug verdicts

Mounjaro vs Zepbound (2026): Same Tirzepatide, Different Labels

Mounjaro (tirzepatide, Eli Lilly) vs Zepbound (tirzepatide, Eli Lilly)

Last verified 2026-05-27

The verdict

Mounjaro and Zepbound are pharmacologically identical — both are tirzepatide manufactured by Eli Lilly. The split is regulatory: Mounjaro carries the FDA label for type 2 diabetes (SURPASS program), while Zepbound carries the labels for chronic weight management (SURMOUNT-1) and obstructive sleep apnea (SURMOUNT-OSA). LillyDirect cash prices are functionally identical at $349 starter / $499 maintenance. The right brand depends on which indication your insurance will cover.

Side-by-side comparison

FieldMounjaroZepbound
Active ingredientTirzepatideTirzepatide
FDA-labeled indicationType 2 diabetes mellitusChronic weight management; obstructive sleep apnea (Dec 2024)
Pivotal trial weight-loss anchor−11.2 kg / 40 weeks (SURPASS-2, 15 mg vs semaglutide)−20.9% TBWL / 72 weeks (SURMOUNT-1, 15 mg)
MechanismDual GIP / GLP-1 receptor agonistDual GIP / GLP-1 receptor agonist
Available doses2.5, 5, 7.5, 10, 12.5, 15 mg (pen + KwikPen + vial)2.5, 5, 7.5, 10, 12.5, 15 mg (pen + KwikPen + vial)
Cash price (LillyDirect direct-pay)$349 starter / $499 maintenance (vial)$349 starter / $499 maintenance (vial)
Commercial insurance PA criteriaA1c ≥6.5% + metformin trial; T2D benefitBMI ≥30 (or ≥27 + comorbidity); obesity benefit (often excluded)
Form factorSingle-dose pen, KwikPen, single-dose vialSingle-dose pen, KwikPen, single-dose vial

Frequently asked questions

Are Mounjaro and Zepbound the same drug?

Yes. Both are tirzepatide manufactured by Eli Lilly — the identical molecule, identical doses (2.5 through 15 mg), and identical mechanism (dual GIP / GLP-1 receptor agonist). Lilly registered the same active ingredient under two brand names so each carries a distinct FDA-labeled indication: Mounjaro for type 2 diabetes (approved May 2022) and Zepbound for chronic weight management (approved November 2023) and obstructive sleep apnea (added December 2024). Pharmacologically interchangeable; regulatory paperwork differs.

Why is Zepbound sometimes cheaper than Mounjaro?

Cash list prices are functionally identical via LillyDirect — both $349 starter / $499 maintenance for single-dose vials. The difference is insurance: many commercial plans cover Mounjaro for documented type 2 diabetes (A1c ≥6.5%) but exclude obesity drugs entirely, leaving Zepbound patients paying cash. Patients without a T2D diagnosis often find Zepbound vials via LillyDirect cheaper than going through pharmacy with no obesity benefit on Mounjaro.

Can I switch from Mounjaro to Zepbound for weight loss?

Clinically, yes — same molecule, same doses, no titration restart needed because dose equivalence is exact (Mounjaro 10 mg equals Zepbound 10 mg). The barrier is administrative: prescribers must write a new prescription under the Zepbound brand, and insurance authorization shifts from a T2D criterion to an obesity criterion (typically BMI ≥30, or ≥27 with weight-related comorbidity). Many patients who lose their T2D diagnosis after weight loss face this transition.

Which is FDA-approved for sleep apnea?

Zepbound only. The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024 based on the SURMOUNT-OSA trials (Malhotra 2024 NEJM, PMID 38912654). Mounjaro is not labeled for OSA despite being the same molecule — the indication is brand-specific because Lilly submitted the OSA application under the Zepbound NDA. Off-label use of Mounjaro for OSA is technically possible but unlikely to be reimbursed.

Are the side effects identical?

Yes. Because the active ingredient is identical, the adverse event profile is identical: nausea (most common, dose-dependent), diarrhea, vomiting, constipation, decreased appetite, and abdominal pain. Both labels carry the same boxed warning for thyroid C-cell tumors observed in rodents. Discontinuation rates due to GI side effects ran 6-7% in SURPASS-2 (Mounjaro) and SURMOUNT-1 (Zepbound) — within trial-design noise. The brand split does not change pharmacology.

Does Mounjaro work for weight loss even though it's not labeled for obesity?

Yes — SURPASS trials in type 2 diabetes consistently showed 11-13 kg weight loss at 15 mg (Frías 2021 NEJM, PMID 34170647), and SURMOUNT-1 in obesity without diabetes showed 20.9% TBWL at the same dose (Jastreboff 2022 NEJM, PMID 35658024). The molecule produces weight loss regardless of which brand is on the label. The labeled-indication distinction matters for insurance coverage and prescribing convention, not biological effect.

References

References

  1. 1.Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  3. 3.Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024. PMID: 38912654.
  4. 4.Eli Lilly and Company. Mounjaro (tirzepatide) injection — FDA prescribing information. DailyMed. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  5. 5.Eli Lilly and Company. Zepbound (tirzepatide) injection — FDA prescribing information. DailyMed. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  6. 6.Eli Lilly and Company. Zepbound SelfPay pricing — $349 starter / $499 maintenance via LillyDirect. Lilly Press Release. 2024. https://www.lilly.com/news/press-releases/lilly-launches-zepbound

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.